INDP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 04:00):

Stats
今日成交量	5 706.00
平均成交量	90 096.00
市值	17.68M
EPS	$0 ( 2024-05-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.130
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Linscott Walt Addison	Buy	75 000	Stock Option (Right to Buy)
2024-01-22	Waltzman Roger J.	Buy	75 000	Stock Option (Right to Buy)
2024-01-22	Sassi Nir	Buy	40 000	Stock Option (Right to Buy)
2024-01-22	Meckler Jeffrey A	Buy	100 000	Stock Option (Right to Buy)
2024-01-22	Newman Michael James	Buy	43 250	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 90 transactions
Buy: 2 551 706 \| Sell: 72 874

Indaptus Therapeutics, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Indaptus Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$-1 284.00 (0.00 %)
EPS:	$-1.840

FY	2023
营收:	$0
毛利润:	$-1 284.00 (0.00 %)
EPS:	$-1.840

FY	2022
营收:	$0
毛利润:	$-1 781.00 (0.00 %)
EPS:	$-1.660

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.890

Financial Reports:

No articles found.

Indaptus Therapeutics,

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

实时更新： Indaptus Therapeutics, [INDP]

Upcoming Earnings Alert